Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.

Matthew S DavidsBryone J KussPeter HillmenMarco MontilloCarol MorenoJames EssellNicole LamannaZsolt NagyConstantine S TamStephan StilgenbauerPaolo GhiaJulio DelgadoStephanie LustgartenDavid T WeaverHagop YoussoufianUlrich Jäger

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Duvelisib demonstrated high response rates with good durability and a manageable safety profile in patients with R/R CLL/SLL who progressed on ofatumumab, including patients with high-risk disease and disease previously refractory to ofatumumab.

Keyphrases

acute lymphoblastic leukemia
acute myeloid leukemia
chronic lymphocytic leukemia
diffuse large b cell lymphoma
randomized controlled trial
multiple myeloma
clinical trial
double blind